Baxalta Innovations GmbH, now part of Shire Clinical Trials
Sponsors / Baxalta Innovations GmbH, now part of Shire
Baxalta Innovations GmbH, now part of Shire is listed as the lead sponsor on 19 clinical trials registered with ClinicalTrials.gov. 0 trials are actively recruiting participants, 0 remain active without open enrollment, and 17 have concluded. 2 of these trials ended early via termination or withdrawal. The cumulative planned enrollment figure across all listed trials is 7,999 participants. All figures are drawn directly from ClinicalTrials.gov and updated as sponsors submit revisions.
19
Total Trials
0
Recruiting
0
Other Active
17
Completed
2
Terminated / Withdrawn
7,999
Total Enrollment
Termination reasons: Other100%
Recent Terminations
- Hemophilia A"Takeda has determined that the benefit/risk profile does not support continuation of the surgery Study for this specific Congenital Hemophilia A with Inhibitors patient population."
- Alpha1-antitrypsin Deficiency
Top Conditions
Hemophilia a (6) Primary immunodeficiency diseases (pid) (3) Acquired hemophilia a (2) Healthy volunteers (2) Alpha1-antitrypsin deficiency (1) Chronic inflammatory demyelinating polyradiculoneuropathy (cidp) (1) Exposure during pregnancy (1) Hemophilia a or b with inhibitors (1) Hemophilia b (1) Von willebrand disease (1)